Effects of sarcosine and N, N-dimethylglycine on NMDA receptor-mediated excitatory field potentials

Mei-Yi Lee, Yi-Ruu Lin, Yi-Shu Tu, Yufeng Jane Tseng, Ming-Huan Chan, Hwei-Hsien Chen, Mei-Yi Lee, Yi-Ruu Lin, Yi-Shu Tu, Yufeng Jane Tseng, Ming-Huan Chan, Hwei-Hsien Chen

Abstract

Background: Sarcosine, a glycine transporter type 1 inhibitor and an N-methyl-D-aspartate (NMDA) receptor co-agonist at the glycine binding site, potentiates NMDA receptor function. Structurally similar to sarcosine, N,N-dimethylglycine (DMG) is also N-methyl glycine-derivative amino acid and commonly used as a dietary supplement. The present study compared the effects of sarcosine and DMG on NMDA receptor-mediated excitatory field potentials (EFPs) in mouse medial prefrontal cortex brain slices using a multi-electrode array system.

Results: Glycine, sarcosine and DMG alone did not alter the NMDA receptor-mediated EFPs, but in combination with glutamate, glycine and its N-methyl derivatives significantly increased the frequency and amplitude of EFPs. The enhancing effects of glycine analogs in combination with glutamate on EFPs were remarkably reduced by the glycine binding site antagonist 7-chlorokynurenate (7-CK). However, DMG, but not sarcosine, reduced the frequency and amplitude of EFPs elicited by co-application of glutamate plus glycine. D-cycloserine, a partial agonist at the glycine binding site on NMDA receptors, affected EFPs in a similar manner to DMG. Furthermore, DMG, but not sarcosine, reduced the frequencies and amplitudes of EFPs elicited by glutamate plus D-serine, another endogenous ligand for glycine binding site.

Conclusions: These findings suggest that sarcosine acts as a full agonist, yet DMG is a partial agonist at glycine binding site of NMDA receptors. The molecular docking analysis indicated that the interactions of glycine, sarcosine, and DMG to NMDA receptors are highly similar, supporting that the glycine binding site of NMDA receptors is a critical target site for sarcosine and DMG.

Keywords: 7-chlorokynurenate; D-cycloserine; D-serine; Glycine binding site; N-methylglycine.

Figures

Fig. 1
Fig. 1
Characterization of NMDA receptor-mediated excitatory field potentials. The experimental protocol (a) and the representative field potential recordings (b) of excitatory filed potentials in an individual prefrontal cortical slice in the presence of TTX (0.3 μM) and bicuculline (10 μM) were shown after the application of glutamate (100 μM) and glycine (10 μM) alone, and then glutamate plus glycine, followed by co-application of glutamate (100 μM) plus glycine (10 μM) with ketamine (10 μM), 7-CK (1 μM), CNQX (10 μM) or D-AP5 (100 μM)
Fig. 2
Fig. 2
Effects of sarcosine and DMG alone or combined with glutamate on excitatory field potentials. The effects of glutamate (100 μM), glycine (10 μM), and glutamate plus glycine were examined prior to the glycine methyl derivatives to verify the slice activity. The experimental protocol (a), the representative field potential recordings (b), and the frequency and amplitude of NMDA receptor-mediated excitatory field potentials after perfusion with sarcosine or DMG (100 μM) alone and various concentrations of sarcosine (c) or DMG (d) (10, 30, and 100 μM) plus glutamate (100 μM). (Frequency: sarcosine F7,21 = 29.43, p < 0.001; DMG F7,21 = 48.94, p < 0.001; Amplitude: sarcosine F7,21 = 28.17, p < 0.001; DMG F7,21 = 5.28, p < 0.001). Data are expressed as percentage of baseline, mean ± SEM (n = 4). ***p < 0.001 compared with baseline
Fig. 3
Fig. 3
Effects of sarcosine or DMG on glutamate/glycine-evoked excitatory field potentials. The experimental protocol (a), the representative field potential recordings (b), and the frequency and amplitude of NMDA receptor-mediated excitatory field potentials (c) after application of glutamate, glycine, glutamate (100 μM) plus glycine (10 μM) and various concentrations (10, 30 and 100 μM) of sarcosine and DMG sequentially with glutamate plus glycine. The data were analyzed by one-way repeated measures ANOVA (Frequency: F9,27 = 50.58, p < 0.001; Amplitude: F9,27 = 54.64, p < 0.001). Data are expressed as percentage of baseline, mean ± SEM (n = 4). ***p < 0.001 compared with baseline. ###p < 0.001 compared with glutamate plus glycine
Fig. 4
Fig. 4
Effects of D-cycloserine on NMDA receptor-mediated excitatory field potentials. The experimental protocol (a), the representative field potential recordings (b), and the frequency and amplitude of NMDA receptor-mediated excitatory field potentials (c) after the application D-cycloserine alone, co-application of D-cycloserine (10 and 30 μM) with glutamate or glutamate plus glycine. The data were analyzed by one-way repeated measures ANOVA (Frequency: F8,24 = 70.25, p < 0.001; Amplitude: F8,24 = 100.8, p < 0.001). Data are expressed as percentage of baseline, mean ± SEM (n = 4). ***p < 0.001 compared with baseline. ###p < 0.001 compared with glutamate plus glycine. DCS:D-cycloserine
Fig. 5
Fig. 5
Effects of 7-CK on excitatory field potentials evoked by co-application of glutamate with sarcosine, DMG and D-cycloserine. The experimental protocol (a) and the frequency and amplitude of NMDA receptor-mediated excitatory field potentials (b) after the application of sarcosine (100 μM), DMG (100 μM), and D-cycloserine (30 μM) plus glutamate with or without 7-CK (1 μM). Two-way repeated measures ANOVA demonstrated significant effects of 7-CK (Frequency: F1,9 = 645.38, p < 0.001; Amplitude: F1,9 = 206.5, p < 0.001). Data are expressed as percentage of baseline, mean ± SEM (n = 4).***p < 0.001 compared with respective controls
Fig. 6
Fig. 6
Effects of sarcosine or DMG on glutamate plus D-serine-evoked excitatory field potentials. The experimental protocol (a) and the frequency and amplitude of NMDA receptor-mediated excitatory field potentials (b) after the application of D-serine alone, D-serine plus glutamate, and co-application of sarcosine or DMG with glutamate plus D-serine were presented. The data were analyzed by one-way repeated measures ANOVA (Frequency: F5,15 = 39.19.43, p < 0.001; Amplitude: F5,15 = 36.79, p < 0.001). Data are expressed as percentage of baseline, mean ± SEM (n = 4). **p < 0.01, ***p < 0.01 compared with baseline. #p < 0.05, ###p < 0.001 compared with glutamate plus D-serine
Fig. 7
Fig. 7
The docked poses of glycine (a), sarcosine (b), and DMG (c) with the NDMA receptor NR1 ligand-binding core (PDB ID: 1 PB7). Ligands were presented as cyan sticks. Potential interacting residues were presented as green lines and labeled with their residue codes and indices. Yellow dashed lines were presented for indicating potential hydrogen bonds (distance <3.5 Å)

References

    1. Bolman WM, Richmond JA. A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. J Autism Dev Disord. 1999;29(3):191–194. doi: 10.1023/A:1023023820671.
    1. Burgdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK, Gross AL, Kroes RA, Moskal JR. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology. 2013;38(5):729–742. doi: 10.1038/npp.2012.246.
    1. Chai GS, Jiang X, Ni ZF, Ma ZW, Xie AJ, Cheng XS, Wang Q, Wang JZ, Liu GP. Betaine attenuates Alzheimer-like pathological changes and memory deficits induced by homocysteine. J Neurochem. 2013;124(3):388–396. doi: 10.1111/jnc.12094.
    1. Chan MH, Chung SS, Stoker AK, Markou A, Chen HH. Sarcosine attenuates toluene-induced motor incoordination, memory impairment, and hypothermia but not brain stimulation reward enhancement in mice. Toxicol Appl Pharmacol. 2012;265(2):158–165. doi: 10.1016/j.taap.2012.10.004.
    1. Chang HJ, Lane HY, Tsai GE. NMDA pathology and treatment of schizophrenia. Curr Pharm Des. 2014;20(32):5118–5126. doi: 10.2174/1381612819666140110121908.
    1. Chen HH, Liao PF, Chan MH. mGluR5 positive modulators both potentiate activation and restore inhibition in NMDA receptors by PKC dependent pathway. J Biomed Sci. 2011;18:19. doi: 10.1186/1423-0127-18-19.
    1. Chen PE, Geballe MT, Katz E, Erreger K, Livesey MR, O’Toole KK, Le P, Lee CJ, Snyder JP, Traynelis SF, Wyllie DJ. Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J Physiol. 2008;586(1):227–245. doi: 10.1113/jphysiol.2007.143172.
    1. Dravid SM, Burger PB, Prakash A, Geballe MT, Yadav R, Le P, Vellano K, Snyder JP, Traynelis SF. Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors. J Neurosci. 2010;30(7):2741–2754. doi: 10.1523/JNEUROSCI.5390-09.2010.
    1. Dunbrack RL., Jr Rotamer libraries in the 21st century. Curr Opin Struct Biol. 2002;12(4):431–440. doi: 10.1016/S0959-440X(02)00344-5.
    1. Dutta A, McKie S, Deakin JF. Ketamine and other potential glutamate antidepressants. Psychiatry Res. 2015;225(1–2):1–13. doi: 10.1016/j.psychres.2014.10.028.
    1. Freed WJ. Prevention of strychnine-induced seizures and death by the N-methylated glycine derivatives betaine, dimethylglycine and sarcosine. Pharmacol Biochem Behav. 1985;22(4):641–643. doi: 10.1016/0091-3057(85)90288-6.
    1. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739–1749. doi: 10.1021/jm0306430.
    1. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 2006;49(21):6177–6196. doi: 10.1021/jm051256o.
    1. Furukawa H, Gouaux E. Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. EMBO J. 2003;22(12):2873–2885. doi: 10.1093/emboj/cdg303.
    1. Graber CD, Goust JM, Glassman AD, Kendall R, Loadholt CB. Immunomodulating properties of dimethylglycine in humans. J Infect Dis. 1981;143(1):101–105. doi: 10.1093/infdis/143.1.101.
    1. Guastella J, Brecha N, Weigmann C, Lester HA, Davidson N. Cloning, expression, and localization of a rat brain high-affinity glycine transporter. Proc Natl Acad Sci U S A. 1992;89(15):7189–7193. doi: 10.1073/pnas.89.15.7189.
    1. Herdon HJ, Godfrey FM, Brown AM, Coulton S, Evans JR, Cairns WJ. Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology. 2001;41(1):88–96. doi: 10.1016/S0028-3908(01)00043-0.
    1. Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P, Tun R, Huang KH, Chang YC, Lane HY, Tsai GE. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry. 2013;74(10):734–741. doi: 10.1016/j.biopsych.2013.02.020.
    1. Kern JK, Miller VS, Cauller PL, Kendall PR, Mehta PJ, Dodd M. Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder. J Child Neurol. 2001;16(3):169–173. doi: 10.1177/088307380101600303.
    1. Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, Chen PW, Tsai G. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry. 2006;60(6):645–649. doi: 10.1016/j.biopsych.2006.04.005.
    1. Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Perng CH, Tsai GE. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008;63(1):9–12. doi: 10.1016/j.biopsych.2007.04.038.
    1. Lanthorn TH. D-Cycloserine: Agonist turned antagonist. Amino Acids. 1994;6(3):247–260. doi: 10.1007/BF00813745.
    1. Lee EJ, Choi SY, Kim E. NMDA receptor dysfunction in autism spectrum disorders. Curr Opin Pharmacol. 2015;20:8–13. doi: 10.1016/j.coph.2014.10.007.
    1. Lin JC, Chan MH, Lee MY, Chen YC, Chen HH. N, N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;71:7–13. doi: 10.1016/j.pnpbp.2016.06.002.
    1. Lopez-Corcuera B, Martinez-Maza R, Nunez E, Roux M, Supplisson S, Aragon C. Differential properties of two stably expressed brain-specific glycine transporters. J Neurochem. 1998;71(5):2211–2219. doi: 10.1046/j.1471-4159.1998.71052211.x.
    1. Moskal JR, Burch R, Burgdorf JS, Kroes RA, Stanton PK, Disterhoft JF, Leander JD. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs. 2014;23(2):243–254. doi: 10.1517/13543784.2014.852536.
    1. Moskal JR, Burgdorf J, Kroes RA, Brudzynski SM, Panksepp J. A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism. Neurosci Biobehav Rev. 2011;35(9):1982–1988. doi: 10.1016/j.neubiorev.2011.06.006.
    1. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–1612. doi: 10.1002/jcc.20084.
    1. Pina-Crespo JC, Talantova M, Micu I, States B, Chen HS, Tu S, Nakanishi N, Tong G, Zhang D, Heinemann SF, Zamponi GW, Stys PK, Lipton SA. Excitatory glycine responses of CNS myelin mediated by NR1/NR3 “NMDA” receptor subunits. J Neurosci. 2010;30(34):11501–11505. doi: 10.1523/JNEUROSCI.1593-10.2010.
    1. Porter DH, Cook RJ, Wagner C. Enzymatic properties of dimethylglycine dehydrogenase and sarcosine dehydrogenase from rat liver. Arch Biochem Biophys. 1985;243(2):396–407. doi: 10.1016/0003-9861(85)90516-8.
    1. Riga D, Matos MR, Glas A, Smit AB, Spijker S, Van den Oever MC. Optogenetic dissection of medial prefrontal cortex circuitry. Front Syst Neurosci. 2014;8:230. doi: 10.3389/fnsys.2014.00230.
    1. Santini AC, Pierantoni GM, Gerlini R, Iorio R, Olabinjo Y, Giovane A, Di Domenico M, Sogos C. Glix 13, a new drug acting on glutamatergic pathways in children and animal models of autism spectrum disorders. Biomed Res Int. 2014;2014:234295. doi: 10.1155/2014/234295.
    1. Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 2011;25(10):859–885. doi: 10.2165/11586650-000000000-00000.
    1. Steve B, Levine DVM, Grant D, Myhre DVM, Guy L, Smith DVM, James G, Burns DVM. Effect of a Nutritional Supplement Containing N,N-Dimethylglycine (DMG) on the Racing Standardbred. Equine Practice 1982, (4):17–20.
    1. Strzelecki D, Szyburska J, Rabe-Jablonska J. Two grams of sarcosine in schizophrenia - is it too much? A potential role of glutamate-serotonin interaction. Neuropsychiatr Dis Treat. 2014;10:263–266. doi: 10.2147/NDT.S54024.
    1. Takahashi T, Sasaki K, Somfai T, Nagai T, Manabe N, Edashige KN. N-Dimethylglycine decreases oxidative stress and improves in vitro development of bovine embryos. J Reprod Dev. 2016;62(2):209–212. doi: 10.1262/jrd.2015-149.
    1. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004;55(5):452–456. doi: 10.1016/j.biopsych.2003.09.012.
    1. Wang H, Stradtman GG, 3rd, Wang XJ, Gao WJ. A specialized NMDA receptor function in layer 5 recurrent microcircuitry of the adult rat prefrontal cortex. Proc Natl Acad Sci U S A. 2008;105(43):16791–16796. doi: 10.1073/pnas.0804318105.
    1. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res. 1990;510(1):158–160. doi: 10.1016/0006-8993(90)90745-W.
    1. Wittwer AJ, Wagner C. Identification of the folate-binding proteins of rat liver mitochondria as dimethylglycine dehydrogenase and sarcosine dehydrogenase. Flavoprotein nature and enzymatic properties of the purified proteins. J Biol Chem. 1981;256(8):4109–4115.
    1. Wolosker H, Dumin E, Balan L, Foltyn VN. D-amino acids in the brain: D-serine in neurotransmission and neurodegeneration. FEBS J. 2008;275(14):3514–3526. doi: 10.1111/j.1742-4658.2008.06515.x.
    1. Won H, Lee HR, Gee HY, Mah W, Kim JI, Lee J, Ha S, Chung C, Jung ES, Cho YS, Park SG, Lee JS, Lee K, Kim D, Bae YC, Kaang BK, Lee MG, Kim E. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature. 2012;486(7402):261–265. doi: 10.1038/nature11208.
    1. Xia RR. Effectiveness of nutritional supplements for reducing symptoms in autism-spectrum disorder: a case report. J Altern Complement Med. 2011;17(3):271–274. doi: 10.1089/acm.2010.0146.
    1. Xu TL, Gong N. Glycine and glycine receptor signaling in hippocampal neurons: diversity, function and regulation. Prog Neurobiol. 2010;91(4):349–361. doi: 10.1016/j.pneurobio.2010.04.008.
    1. Zhang HX, Hyrc K, Thio LL. The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine. J Physiol. 2009;587(Pt 13):3207–3220. doi: 10.1113/jphysiol.2009.168757.
    1. Zhang HX, Lyons-Warren A, Thio LL. The glycine transport inhibitor sarcosine is an inhibitory glycine receptor agonist. Neuropharmacology. 2009;57(5–6):551–555. doi: 10.1016/j.neuropharm.2009.07.019.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する